Cargando…

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma

Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in ABC DLBCL and may augment salvage chemotherapy. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Wyndham H., Phillips, Tycel, Popplewell, Leslie, de Vos, Sven, Chhabra, Saurabh, Kimball, Amy S., Beaupre, Darrin, Huang, Da Wei, Wright, George, Kwei, Kevin, Ping, Jerry, Neuenburg, Jutta K., Staudt, Louis M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907362/ https://www.ncbi.nlm.nih.gov/pubmed/33856277 http://dx.doi.org/10.1080/10428194.2021.1907371

Ejemplares similares

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2022)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
por: Wang, Michael, et al.
Publicado: (2017)

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
por: Lakhotia, Rahul, et al.
Publicado: (2023)

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
por: Melani, Christopher, et al.
Publicado: (2018)

Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?
por: Jessamy, Kegan, et al.
Publicado: (2016)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement
por: Kojima, Minoru, et al.
Publicado: (2020)

P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES
por: Vassilakopoulos, T., et al.
Publicado: (2022)

P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
por: Biran, Noa, et al.
Publicado: (2019)

The cubist epoch
por: Cooper, Douglas, 1911-1984
Publicado: (1970)

The Psychology of Epochs
Publicado: (1852)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2020)

P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS
por: Vassilakopoulos, T., et al.
Publicado: (2022)

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
por: Dodero, A., et al.
Publicado: (2019)

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Targets for Ibrutinib Beyond B Cell Malignancies
por: Berglöf, A., et al.
Publicado: (2015)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
por: Woyach, Jennifer A., et al.
Publicado: (2023)

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

Lenalidomide in Diffuse Large B-Cell Lymphoma
por: Thieblemont, Catherine, et al.
Publicado: (2012)

Mengelberg and the symphonic epoch
por: Sollitt, Edna Richolson
Publicado: (1929)

Epochs in the History of Obstetrics
por: Greer, H. L. H.
Publicado: (1935)

The epochs of international law
por: Grewe, Wilhelm G, et al.
Publicado: (2000)

Physicists: epoch and personalities
por: Feinberg, E L, et al.
Publicado: (2011)

The New Epoch in Medicine
por: Ormiston, Robert
Publicado: (1889)

An Epoch in Medical History
Publicado: (1892)

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2019)

Inhibition of effector B cells by ibrutinib in systemic sclerosis
por: Einhaus, Jakob, et al.
Publicado: (2020)

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
por: Muñoz, Javier, et al.
Publicado: (2023)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
por: Hansson, Lotta, et al.
Publicado: (2017)

Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients
por: Pejša, Vlatko, et al.
Publicado: (2017)

P1121: POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

An Important Epoch in Medical Education
Publicado: (1914)

Some Personalities of the Hunterian Epoch
por: Woolf, A. E. Mortimer
Publicado: (1929)

Cannot write session to /tmp/vufind_sessions/sess_6vnkduaf0713e3eiclsrfanfmm